Dialectic Therapeutics Receives FDA Clearance of IND Application for for Its Lead Product Candidate To Treat Cancer
UF startup Dialectic Therapeutics, Inc., a Texas-based biotechnology company focused on creating innovative new technologies to treat cancer, announced that the U.S. Food and Drug Administration (FDA) has concluded that Dialectic may proceed with its clinical investigation for its lead product candidate, DT2216, a unique compound built using its proprietary and novel Antiapoptotic Protein Targeted Degradation (APTaD) technology.
Secretary of State for Industry Considers SATLANTIS “One of the Most Important New Space Industrial Realities in Spain”
The Secretary of State for Industry in Spain, Raúl Blanco, considers that UF startup and UF Innovate | The Hub resident client SATLANTIS, a company specializing in high-performance optical loads for observation of the Earth for small satellites, is one of the most important industrial realities of New Space in Spain.
New OxThera/Oxabact US Patent Granted
UF startup OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces that a new US patent has been granted for its product candidate Oxabact and a method for the treatment or prevention of an oxalate-related disorder, such as hyperoxaluria.
Cannabix Technologies Develops Version 3.0 of THC Breath Analyzer Device
UF startup Cannabix Technologies Inc., developer of the Cannabix Marijuana Breathalyzer devices for law enforcement and the workplace, has developed the latest version of the THC Breath Analyzer (THCBA) prototype and portable system for field use.
Biotech Firm Raises $20 Million, Sees Progress on COVID-19 Vaccine
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc. has raised $20 million from the sale of common stock and will use some of the funding to boost its research into a Covid-19 vaccine.
Abfero Pharmaceuticals Announces Initiation of Phase 1 Study for Lead Iron Chelator
UF startup AbFero Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of its lead iron chelator, SP-420, in myelodysplastic (MDS) and myelofibrosis patients (MF) with transfusional iron overload (TIO).
Plasma Oxalate and Kidney Function Are Correlated in Patients With Primary Hyperoxaluria With Maintained Kidney Function – Data From Three Placebo-Controlled Studies Published
UF startup OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces the publication of an article in Pediatric Nephrology, on the significant correlation between plasma oxalate and kidney function in three controlled clinical trials with PH patients.
AbFero Pharmaceuticals Announces Funding From Cure Parkinson’s for Lead Compound SP-420
AbFero Ltd., a subsidiary of UF startup AbFero Pharmaceuticals, Inc., a privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload, announced the award of a grant from Cure Parkinson's for the development of their lead, brain-penetrant iron chelating agent, SP-420, as a disease modifying therapy for Parkinson's disease (PD).
DNAtrix Announces Preclinical Data Demonstrating Anti-Tumor Activity of DNX-2401 in Models of Pediatric Tumors Published in Clinical Cancer Research
UF startup DNAtrix, a biotech company advancing virus-driven immunotherapies for cancer, announced preclinical data evaluating the use of DNX-2401 against the pediatric brain malignancies atypical teratoid/rhabdoid tumor (AT/RT) and primitive neuroectodermal tumors (PNETs) was published in Clinical Cancer Research.
ASABE names AGROVIEW winner of a 2021 AE50 award
The American Society of Agricultural and Biological Engineers (ASABE) has named AGROVIEW winner of a 2021 AE50 award.
